Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients.
Cranial palsy
Immune checkpoint inhibitors
Immune-related adverse events
Ipilimumab
Nivolumab
Pembrolizumab
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
received:
13
07
2024
accepted:
22
08
2024
revised:
20
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
Describe the demographic data and clinical phenotype of cranial palsy induced by immune checkpoint inhibitors (CNP-ICI). A systematic literature review of the literature was performed in Pubmed, Web of Science, and Embase, including 68 articles and 136 patients (PROSPERO no. CRD42024517262). Out of the 1205 articles screened, 68 articles were included after fulfilling the inclusion criteria, for a total of 136 patients. All articles were case reports and case series. In the cohort studied, 52% of patients were treated with anti PD-1/PDL-1 therapies, 14% with anti CTLA-4 therapies, and 34% with a combination of anti CTLA-4 and anti PD-1/PDL-1 therapies. The facial nerve was the most affected cranial nerve, involved in 38% of cases, followed by the optic nerve (35%), the cochleovestibular nerve (12%), and the abducens nerve (10%). The median time from the initial immune checkpoint inhibitor (ICI) injection to the onset CNP-ICI was 10 weeks (IQR 4-20). Magnetic resonance imaging demonstrated contrast enhancement or abnormal signal of the affected nerve in 43% of cases. Cerebrospinal fluid analysis indicated lymphocytic pleocytosis in 59% of cases. At the onset of immune-related adverse events, 89% of patients discontinued immunotherapy, and 92% received treatment for CNP-ICI. Treatment regimens included corticosteroids in 86% of cases, intravenous immunoglobulin in 21%, and plasma exchange in 5.1%. Among the whole population, 33% achieved recovery, 52% showed clinical improvement, 16% remained stable, and 3% experienced worsening of their condition. Rechallenge with immunotherapy was significantly associated with the emergence of new immune-related Adverse Events (irAEs). ICI therapy may lead to cranial nerve involvement, particularly affecting the facial nerve, typically presenting around 10 weeks after treatment initiation. While corticosteroid therapy often resulted in patient improvement, rechallenging with ICIs were associated with new irAEs.
Identifiants
pubmed: 39225744
doi: 10.1007/s00415-024-12660-2
pii: 10.1007/s00415-024-12660-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801. https://doi.org/10.1038/s41467-020-17670-y
doi: 10.1038/s41467-020-17670-y
pubmed: 32732879
pmcid: 7393098
Mamdani H, Matosevic S, Khalid AB et al (2022) Immunotherapy in lung cancer: current landscape and future directions. Front Immunol 13:823618
doi: 10.3389/fimmu.2022.823618
pubmed: 35222404
pmcid: 8864096
Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480–1492. https://doi.org/10.1016/S1470-2045(18)30700-9
doi: 10.1016/S1470-2045(18)30700-9
pubmed: 30361170
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355. https://doi.org/10.1126/science.aar4060
doi: 10.1126/science.aar4060
pubmed: 29567705
pmcid: 7391259
Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. https://doi.org/10.1016/j.ejca.2015.11.016
doi: 10.1016/j.ejca.2015.11.016
pubmed: 26765102
Gougis P, Jochum F, Abbar B et al (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. eClinicalMedicine 70:102536. https://doi.org/10.1016/j.eclinm.2024.102536
doi: 10.1016/j.eclinm.2024.102536
pubmed: 38560659
pmcid: 10981010
Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1–8. https://doi.org/10.1016/j.ejca.2016.12.001
doi: 10.1016/j.ejca.2016.12.001
pubmed: 28064139
Xu M, Nie Y, Yang Y et al (2019) Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis. Neurologist 24:75–83. https://doi.org/10.1097/NRL.0000000000000230
doi: 10.1097/NRL.0000000000000230
pubmed: 31045716
Vogrig A, Muñiz-Castrillo S, Joubert B et al (2021) Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. https://doi.org/10.1212/WNL.0000000000011340
doi: 10.1212/WNL.0000000000011340
pubmed: 34799461
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8479591
Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23:60–63. https://doi.org/10.1136/bmjebm-2017-110853
doi: 10.1136/bmjebm-2017-110853
pubmed: 29420178
pmcid: 6234235
Oguri T, Sasada S, Shimizu S et al (2021) A case of Guillain–Barré syndrome and Stevens-Johnson syndrome/toxic epidermal necrosis overlap after pembrolizumab treatment. J Investig Med High Impact Case Rep 9:232470962110374. https://doi.org/10.1177/23247096211037462
doi: 10.1177/23247096211037462
Xie K, Kong C, Mehta MC (2020) A case of melanoma-associated retinopathy, uveitis, and optic neuritis associated with pembrolizumab, managed with topical, intravitreal, and intravenous steroids. J Vitreoretin Dis 4:220–226. https://doi.org/10.1177/2474126419886154
doi: 10.1177/2474126419886154
pubmed: 37007447
Ogawa M, Tateishi Y, Suzuki H et al (2020) A case of non-small-cell lung cancer with acute optic neuritis observed after pembrolizumab treatment. Haigan 60:385–389. https://doi.org/10.2482/haigan.60.385
doi: 10.2482/haigan.60.385
McNeill CJ, Fehmi J, Gladwin J, Price C (2019) A rare case of Miller Fisher variant of Guillain–Barré syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep 12:e229443. https://doi.org/10.1136/bcr-2019-229443
doi: 10.1136/bcr-2019-229443
pubmed: 31413049
pmcid: 6700679
Wilson MA, Guld K, Galetta S et al (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4:66. https://doi.org/10.1186/s40425-016-0170-9
doi: 10.1186/s40425-016-0170-9
pubmed: 27777775
pmcid: 5067900
Kichloo A, Albosta MS, Jamal SM et al (2020) Atezolizumab-induced Bell’s palsy in a patient with small cell lung cancer. J Investig Med High Impact Case Rep 8:232470962096501. https://doi.org/10.1177/2324709620965010
doi: 10.1177/2324709620965010
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol 16:589–593. https://doi.org/10.1093/neuonc/nou001
doi: 10.1093/neuonc/nou001
pubmed: 24482447
pmcid: 3956363
Zieman D, Frankel AE (2019) Autoimmune Bell’s palsy following immunotherapy for metastatic melanoma: a report of 2 cases. J Immunother 42:318–320. https://doi.org/10.1097/CJI.0000000000000291
doi: 10.1097/CJI.0000000000000291
pubmed: 31318723
Takemura K, Yamanaka T, Hayashida M et al (2023) Bell’s palsy during rechallenge of immune checkpoint inhibitor. IJU Case Rep 6:144–146. https://doi.org/10.1002/iju5.12572
doi: 10.1002/iju5.12572
pubmed: 36875003
pmcid: 9978074
Numata S, Iwata Y, Okumura R et al (2018) Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: a case report. J Dermatol 45:113–114. https://doi.org/10.1111/1346-8138.13779
doi: 10.1111/1346-8138.13779
pubmed: 28225147
Altman AL, Golub JS, Pensak ML, Samy RN (2015) Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol Neck Surg 153:894–895. https://doi.org/10.1177/0194599815606701
doi: 10.1177/0194599815606701
Vicente-Pascual M, Molins-Rojas C, Rosas-Soto K et al (2021) Bilateral optic neuritis secondary to immune etiology by anti-PD-L1 antibody. J Neuroophthalmol 41:e177–e179. https://doi.org/10.1097/WNO.0000000000001029
doi: 10.1097/WNO.0000000000001029
pubmed: 32868568
Kartal Ö, Ataş E (2018) Bilateral optic neuritis secondary to nivolumab therapy: a case report. Medicina (Mex) 54:82. https://doi.org/10.3390/medicina54050082
doi: 10.3390/medicina54050082
Willegers T, Janssen JBE, Boers-Sonderen MJ, Bekkers S (2020) Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report. J Immunother 43:93–94. https://doi.org/10.1097/CJI.0000000000000310
doi: 10.1097/CJI.0000000000000310
pubmed: 32011418
Hou Y, Su Q, Tang S, Li H (2022) Camrelizumab-induced isolate abducens neuritis: a rare ophthalmic immune-related adverse events. Brain Sci 12:1242. https://doi.org/10.3390/brainsci12091242
doi: 10.3390/brainsci12091242
pubmed: 36138977
pmcid: 9496756
Wang Q, Yan X, Li J (2022) Camrelizumab-induced isolated abducens nerve palsy. Adv Drug React J. https://doi.org/10.3760/cma.j.cn114015-20220119-00049
doi: 10.3760/cma.j.cn114015-20220119-00049
Wako S, Ikeguchi R, Toda K et al (2023) Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: a case report. J Neuroimmunol 374:578010. https://doi.org/10.1016/j.jneuroim.2022.578010
doi: 10.1016/j.jneuroim.2022.578010
pubmed: 36508929
Diamanti L, Picca A, Bini P et al (2022) Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurol Sci 43:2031–2041. https://doi.org/10.1007/s10072-021-05561-z
doi: 10.1007/s10072-021-05561-z
pubmed: 34424427
Patel AS, Snook RJ, Sehdev A (2019) Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discov Med 28:107–111
pubmed: 31926582
Lemasson J, Cuzzubbo S, Doucet L et al (2019) Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. Eur J Cancer 117:116–118. https://doi.org/10.1016/j.ejca.2019.05.022
doi: 10.1016/j.ejca.2019.05.022
pubmed: 31279302
Diamantopoulos PT, Tsatsou K, Benopoulou O et al (2020) Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma. Melanoma Res 30:484–491. https://doi.org/10.1097/CMR.0000000000000681
doi: 10.1097/CMR.0000000000000681
pubmed: 32898389
Bolz S, Ramakrishnan T, Fleischer M et al (2021) Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci 22:100324. https://doi.org/10.1016/j.ensci.2021.100324
doi: 10.1016/j.ensci.2021.100324
pubmed: 33604462
pmcid: 7876540
Zecchini JM, Kim S, Yum K, Friedlander P (2018) Development of Bell’s palsy after treatment with ipilimumab and nivolumab for metastatic melanoma: a case report. J Immunother 41:39–41. https://doi.org/10.1097/CJI.0000000000000184
doi: 10.1097/CJI.0000000000000184
pubmed: 28926356
Nowosielski M, Di Pauli F, Iglseder S et al (2020) Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 7:e773. https://doi.org/10.1212/NXI.0000000000000773
doi: 10.1212/NXI.0000000000000773
pubmed: 32461353
pmcid: 7286649
Yost MD, Chou CZ, Botha H et al (2017) Facial diplegia after pembrolizumab treatment. Muscle Nerve. https://doi.org/10.1002/mus.25663
doi: 10.1002/mus.25663
pubmed: 28398689
Yuen C, Reid P, Zhang Z et al (2019) Facial palsy induced by checkpoint blockade: a single center retrospective study. J Immunother 42:94–96. https://doi.org/10.1097/CJI.0000000000000254
doi: 10.1097/CJI.0000000000000254
pubmed: 30614917
Green KE, Levine AM, Ward JH, Kaufman DI (2019) GQ1b-seronegative miller fisher syndrome associated with pembrolizumab. J Neuroophthalmol 39:394–396. https://doi.org/10.1097/WNO.0000000000000755
doi: 10.1097/WNO.0000000000000755
pubmed: 30801443
Ong S, Chapman J, Young G, Mansy T (2018) Guillain–Barré-like syndrome during pembrolizumab treatment. Muscle Nerve. https://doi.org/10.1002/mus.26101
doi: 10.1002/mus.26101
pubmed: 29443381
Francis JH, Jaben K, Santomasso BD et al (2020) Immune checkpoint inhibitor-associated optic neuritis. Ophthalmology 127:1585–1589. https://doi.org/10.1016/j.ophtha.2020.05.003
doi: 10.1016/j.ophtha.2020.05.003
pubmed: 32437864
Beninato T, Fucà G, Di Guardo L et al (2021) Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors. Melanoma Res 31:178–180. https://doi.org/10.1097/CMR.0000000000000715
doi: 10.1097/CMR.0000000000000715
pubmed: 33492050
Yeh OL, Francis CE (2015) Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol 35:144–147. https://doi.org/10.1097/WNO.0000000000000217
doi: 10.1097/WNO.0000000000000217
pubmed: 25647225
Jaben KA, Francis JH, Shoushtari AN, Abramson DH (2020) Isolated abducens nerve palsy following pembrolizumab. Neuro-Ophthalmol 44:182–185. https://doi.org/10.1080/01658107.2019.1566385
doi: 10.1080/01658107.2019.1566385
Makri OE, Dimitrakopoulos F-I, Tsapardoni F et al (2022) Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. Int J Neurosci 132:643–648. https://doi.org/10.1080/00207454.2020.1831489
doi: 10.1080/00207454.2020.1831489
pubmed: 32998608
Manousakis G, Koch J, Sommerville RB et al (2013) Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 48:440–444. https://doi.org/10.1002/mus.23830
doi: 10.1002/mus.23830
pubmed: 23447136
Siegel CH, Finn RS, Ho MG (2018) Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma. Mayo Clin Proc 93:540–541. https://doi.org/10.1016/j.mayocp.2018.01.001
doi: 10.1016/j.mayocp.2018.01.001
pubmed: 29622100
Nishimura T, Sakatani T, Takeshima H et al (2022) Multiple cranial neuropathies similar to orbital apex syndrome associated with pembrolizumab: a case report. Case Rep Oncol 15:868–873. https://doi.org/10.1159/000526901
doi: 10.1159/000526901
pubmed: 36825096
pmcid: 9941785
Sun MM, Seleme N, Chen JJ et al (2021) Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuroophthalmol 41:519–530. https://doi.org/10.1097/WNO.0000000000001148
doi: 10.1097/WNO.0000000000001148
pubmed: 33136674
Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216. https://doi.org/10.1001/jamaneurol.2017.1912
doi: 10.1001/jamaneurol.2017.1912
pubmed: 28873125
pmcid: 5710300
Plaçais L, Michot J-M, Champiat S et al (2021) Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun 3:fcab220. https://doi.org/10.1093/braincomms/fcab220
doi: 10.1093/braincomms/fcab220
pubmed: 34651126
pmcid: 8505025
Farina A, Birzu C, Elsensohn M-H et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5:fcad169. https://doi.org/10.1093/braincomms/fcad169
doi: 10.1093/braincomms/fcad169
pubmed: 37389303
pmcid: 10306160
Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225. https://doi.org/10.1016/j.ejca.2016.02.024
doi: 10.1016/j.ejca.2016.02.024
pubmed: 27084345
Dinoto A, McKeon A, Vattemi G et al (2022) Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma. J Neuroimmunol 368:577882. https://doi.org/10.1016/j.jneuroim.2022.577882
doi: 10.1016/j.jneuroim.2022.577882
pubmed: 35580403
pmcid: 9637407
Cordes LM, Davarpanah NN, Reoma LB et al (2020) Neurotoxicities associated with checkpoint inhibitors: two case reports and a review of the literature. Clin Case Rep 8:24–32. https://doi.org/10.1002/ccr3.2534
doi: 10.1002/ccr3.2534
pubmed: 31998480
Duong SL, Barbiero FJ, Nowak RJ, Baehring JM (2021) Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol 152:265–277. https://doi.org/10.1007/s11060-021-03695-w
doi: 10.1007/s11060-021-03695-w
pubmed: 33454891
Nukui T, Nakayama Y, Yamamoto M et al (2018) Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain–Barré syndrome. J Neurol Sci 390:115–116. https://doi.org/10.1016/j.jns.2018.04.028
doi: 10.1016/j.jns.2018.04.028
pubmed: 29801870
Noble CW, Gangaputra SS, Thompson IA et al (2020) Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm 28:854–859. https://doi.org/10.1080/09273948.2019.1583347
doi: 10.1080/09273948.2019.1583347
pubmed: 31013173
Parikh RA, Chaon BC, Berkenstock MK (2021) Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm 29:1585–1590. https://doi.org/10.1080/09273948.2020.1766082
doi: 10.1080/09273948.2020.1766082
pubmed: 32643982
Kim JM, Materin MA, Sznol M et al (2019) Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology 126:1058–1062. https://doi.org/10.1016/j.ophtha.2019.01.031
doi: 10.1016/j.ophtha.2019.01.031
pubmed: 30735682
Mori S, Kurimoto T, Ueda K et al (2018) Optic neuritis possibly induced by anti-PD-L1 antibody treatment in a patient with non-small cell lung carcinoma. Case Rep Ophthalmol 9:348–356. https://doi.org/10.1159/000491075
doi: 10.1159/000491075
pubmed: 30140221
pmcid: 6103362
SengulSamanci N, Ozan T, Çelik E, Demirelli FH (2020) Optic neuritis related to atezolizumab treatment in a patient with metastatic non–small-cell lung cancer. JCO Oncol Pract 16:96–98. https://doi.org/10.1200/JOP.19.00438
doi: 10.1200/JOP.19.00438
Mirabile A, Brioschi E, Ducceschi M et al (2019) PD-1 inhibitors-related neurological toxicities in patients with non-small-cell lung cancer: a literature review. Cancers 11:296. https://doi.org/10.3390/cancers11030296
doi: 10.3390/cancers11030296
pubmed: 30832285
pmcid: 6468526
De Maleissye M-F, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375:296–297. https://doi.org/10.1056/NEJMc1515584
doi: 10.1056/NEJMc1515584
pubmed: 27468083
Bruno F, Palmiero RA, Ferrero B et al (2021) Pembrolizumab-induced isolated cranial neuropathy: a rare case report and review of literature. Front Neurol 12:669493. https://doi.org/10.3389/fneur.2021.669493
doi: 10.3389/fneur.2021.669493
pubmed: 34046006
pmcid: 8144636
Daetwyler E, Zippelius A, Meyer P, Läubli H (2023) Pembrolizumab-induced optic neuropathy—a case report. Front Immunol 14:1171981. https://doi.org/10.3389/fimmu.2023.1171981
doi: 10.3389/fimmu.2023.1171981
pubmed: 37228591
pmcid: 10203429
Rossi S, Gelsomino F, Rinaldi R et al (2023) Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J Neurol 270:2975–2986. https://doi.org/10.1007/s00415-023-11625-1
doi: 10.1007/s00415-023-11625-1
pubmed: 36800019
pmcid: 10188572
Ahluwalia A, Kohli AA (2021) Photopsias in the setting of nivolumab therapy. J Neuroophthalmol 41:e25–e26. https://doi.org/10.1097/WNO.0000000000000909
doi: 10.1097/WNO.0000000000000909
pubmed: 32108668
Kawakado K, Tamura T, Nakanishi M et al (2021) Retrobulbar optic neuritis induced by pembrolizumab in a patient with lung adenocarcinoma. Intern Med 60:3941–3945. https://doi.org/10.2169/internalmedicine.7425-21
doi: 10.2169/internalmedicine.7425-21
pubmed: 34148963
pmcid: 8758449
Boisseau W, Touat M, Berzero G et al (2017) Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. Eur J Cancer 83:28–31. https://doi.org/10.1016/j.ejca.2017.05.036
doi: 10.1016/j.ejca.2017.05.036
pubmed: 28710954
Wilson R, Menassa DA, Davies AJ et al (2018) Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol 5:640–645. https://doi.org/10.1002/acn3.547
doi: 10.1002/acn3.547
pubmed: 29761126
pmcid: 5945956
Kambayashi Y, Fujimura T, Kuroda H et al (2020) Severe demyelinating neuropathy in an advanced melanoma patient treated with nivolumab plus ipilimumab combined therapy. Case Rep Oncol 13:474–477. https://doi.org/10.1159/000506976
doi: 10.1159/000506976
pubmed: 32508619
pmcid: 7250384
Bompaire F, Mateus C, Taillia H et al (2012) Severe meningo-radiculo-nevritis associated with ipilimumab. Invest New Drugs 30:2407–2410. https://doi.org/10.1007/s10637-011-9787-1
doi: 10.1007/s10637-011-9787-1
pubmed: 22231551
Mancone S, Lycan T, Ahmed T et al (2018) Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol 265:1636–1642. https://doi.org/10.1007/s00415-018-8890-z
doi: 10.1007/s00415-018-8890-z
pubmed: 29761297
Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659–669. https://doi.org/10.1002/ana.25708
doi: 10.1002/ana.25708
pubmed: 32086972
Ruff MW, Mauermann ML (2018) The mayo clinic experience with the neurological complications of the CTLA-4 inhibitor ipilimumab. Neurologist 23:98–99. https://doi.org/10.1097/NRL.0000000000000176
doi: 10.1097/NRL.0000000000000176
pubmed: 29722744
Missori P, Ambrosone A, Cristofani L et al (2022) Third cranial nerve palsy after monoclonal antibody therapy for lung cancer: a case report. Case Rep Ophthalmol 13:282–285. https://doi.org/10.1159/000524114
doi: 10.1159/000524114
pubmed: 35702522
pmcid: 9149351
Dubey D, David WS, Amato AA et al (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. https://doi.org/10.1212/WNL.0000000000008091
doi: 10.1212/WNL.0000000000008091
pubmed: 31624089
Aya F, Ruiz-Esquide V, Viladot M et al (2017) Vasculitic neuropathy induced by pembrolizumab. Ann Oncol 28:433–434. https://doi.org/10.1093/annonc/mdw613
doi: 10.1093/annonc/mdw613
pubmed: 27864214
Gaudin RA, Jowett N, Banks CA et al (2016) Bilateral facial paralysis: a 13-year experience. Plast Reconstr Surg 138:879–887. https://doi.org/10.1097/PRS.0000000000002599
doi: 10.1097/PRS.0000000000002599
pubmed: 27307336
Yanagihara N, Mori H, Kozawa T et al (1984) Bell’s palsy: nonrecurrent v recurrent and unilateral v bilateral. Arch Otolaryngol Head Neck Surg 110:374–377. https://doi.org/10.1001/archotol.1984.00800320028006
doi: 10.1001/archotol.1984.00800320028006
Allenbach Y, Anquetil C, Manouchehri A et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586. https://doi.org/10.1016/j.autrev.2020.102586
doi: 10.1016/j.autrev.2020.102586
pubmed: 32535094
Touat M, Maisonobe T, Knauss S et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. https://doi.org/10.1212/WNL.0000000000006124
doi: 10.1212/WNL.0000000000006124
pubmed: 30120137
pmcid: 9694795
Salem J-E, Bretagne M, Abbar B et al (2023) Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 13:1100–1115. https://doi.org/10.1158/2159-8290.CD-22-1180
doi: 10.1158/2159-8290.CD-22-1180
pubmed: 36815259
Lehmann LH, Heckmann MB, Bailly G et al (2023) Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation 148:473–486. https://doi.org/10.1161/CIRCULATIONAHA.123.062405
doi: 10.1161/CIRCULATIONAHA.123.062405
pubmed: 37317858
pmcid: 10527069
Clarke JL, Perez HR, Jacks LM et al (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449–1454. https://doi.org/10.1212/WNL.0b013e3181dc1a69
doi: 10.1212/WNL.0b013e3181dc1a69
pubmed: 20439847
pmcid: 2871005
Pavlidis N (2004) The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol 15:iv285–iv291. https://doi.org/10.1093/annonc/mdh941
doi: 10.1093/annonc/mdh941
pubmed: 15477323
Giles AJ, Hutchinson M-KND, Sonnemann HM et al (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6:51. https://doi.org/10.1186/s40425-018-0371-5
doi: 10.1186/s40425-018-0371-5
pubmed: 29891009
pmcid: 5996496
Maeda N, Maruhashi T, Sugiura D et al (2019) Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells. J Biol Chem 294:19896–19906. https://doi.org/10.1074/jbc.RA119.010379
doi: 10.1074/jbc.RA119.010379
pubmed: 31723031
pmcid: 6937557
Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142. https://doi.org/10.1093/annonc/mdx225
doi: 10.1093/annonc/mdx225
pubmed: 28881921
Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: asco guideline update. J Clin Oncol 39:4073–4126. https://doi.org/10.1200/JCO.21.01440
doi: 10.1200/JCO.21.01440
pubmed: 34724392
Tomsitz D, Ruf T, Zierold S et al (2023) Steroid-refractory immune-related adverse events induced by checkpoint inhibitors. Cancers 15:2538. https://doi.org/10.3390/cancers15092538
doi: 10.3390/cancers15092538
pubmed: 37174003
pmcid: 10177379
Janssen JBE, Leow TYS, Herbschleb KH et al (2021) Immune checkpoint inhibitor–related guillain-barré syndrome: a case series and review of the literature. J Immunother 44:276–282. https://doi.org/10.1097/CJI.0000000000000364
doi: 10.1097/CJI.0000000000000364
pubmed: 33758147
Katsumoto TR, Wilson KL, Giri VK et al (2022) Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity? Immunother Adv 2:ltac012. https://doi.org/10.1093/immadv/ltac012
doi: 10.1093/immadv/ltac012
pubmed: 35814850
pmcid: 9257781
Zhao Q, Zhang J, Xu L et al (2021) Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis. Front Immunol 12:730320. https://doi.org/10.3389/fimmu.2021.730320
doi: 10.3389/fimmu.2021.730320
pubmed: 34646270
pmcid: 8503641
Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865. https://doi.org/10.1001/jamaoncol.2020.0726
doi: 10.1001/jamaoncol.2020.0726
pubmed: 32297899
Owen CN, Bai X, Quah T et al (2021) Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32:917–925. https://doi.org/10.1016/j.annonc.2021.03.204
doi: 10.1016/j.annonc.2021.03.204
pubmed: 33798657
Couey MA, Bell RB, Patel AA et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7:165. https://doi.org/10.1186/s40425-019-0645-6
doi: 10.1186/s40425-019-0645-6
pubmed: 31269983
pmcid: 6609357
Wang DY, Salem J-E, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721. https://doi.org/10.1001/jamaoncol.2018.3923
doi: 10.1001/jamaoncol.2018.3923
pubmed: 30242316
pmcid: 6440712
Fonseca E, Cabrera-Maqueda JM, Ruiz-García R et al (2023) Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol 22:1150–1159. https://doi.org/10.1016/S1474-4422(23)00335-6
doi: 10.1016/S1474-4422(23)00335-6
pubmed: 37977714
Dall’Olio FG, Rizzo A, Mollica V et al (2021) Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 13:257–270. https://doi.org/10.2217/imt-2020-0179
doi: 10.2217/imt-2020-0179
pubmed: 33225800
Kfoury M, Najean M, Lappara A et al (2022) Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treat Rev 110:102452. https://doi.org/10.1016/j.ctrv.2022.102452
doi: 10.1016/j.ctrv.2022.102452
pubmed: 35998515
Zhong L, Wu Q, Chen F et al (2021) Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother 70:2559–2576. https://doi.org/10.1007/s00262-020-02803-5
doi: 10.1007/s00262-020-02803-5
pubmed: 33576872
pmcid: 10991616
Maher VE, Fernandes LL, Weinstock C et al (2019) Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol 37:2730–2737. https://doi.org/10.1200/JCO.19.00318
doi: 10.1200/JCO.19.00318
pubmed: 31116675
Verheijden RJ, Van Eijs MJM, May AM et al (2023) Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol 7:41. https://doi.org/10.1038/s41698-023-00380-1
doi: 10.1038/s41698-023-00380-1
pubmed: 37173424
pmcid: 10182067
Tokunaga A, Sugiyama D, Maeda Y et al (2019) Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. J Exp Med 216:2701–2713. https://doi.org/10.1084/jem.20190738
doi: 10.1084/jem.20190738
pubmed: 31537643
pmcid: 6888983
Iorgulescu JB, Gokhale PC, Speranza MC et al (2021) Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin Cancer Res 27:276–287. https://doi.org/10.1158/1078-0432.CCR-20-2291
doi: 10.1158/1078-0432.CCR-20-2291
pubmed: 33239433
Tarhini AA, Kang N, Lee SJ et al (2021) Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer 9:e002535. https://doi.org/10.1136/jitc-2021-002535
doi: 10.1136/jitc-2021-002535
pubmed: 33963015
pmcid: 8108687
Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124:3706–3714. https://doi.org/10.1002/cncr.31629
doi: 10.1002/cncr.31629
pubmed: 29975414
Simpson TR, Li F, Montalvo-Ortiz W et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med 210:1695–1710. https://doi.org/10.1084/jem.20130579
doi: 10.1084/jem.20130579
pubmed: 23897981
pmcid: 3754863
Nishimura H, Nose M, Hiai H et al (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151. https://doi.org/10.1016/S1074-7613(00)80089-8
doi: 10.1016/S1074-7613(00)80089-8
pubmed: 10485649
Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primer 6:38. https://doi.org/10.1038/s41572-020-0160-6
doi: 10.1038/s41572-020-0160-6
Axelrod ML, Meijers WC, Screever EM et al (2022) T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature 611:818–826. https://doi.org/10.1038/s41586-022-05432-3
doi: 10.1038/s41586-022-05432-3
pubmed: 36385524
pmcid: 9930174
Fenioux C, Abbar B, Boussouar S et al (2024) Publisher correction: thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 30:910–910. https://doi.org/10.1038/s41591-023-02771-0
doi: 10.1038/s41591-023-02771-0
pubmed: 38172633